Dexcom launches Flex CGM for type 2 diabetes Germany

Dexcom has launched its Flex continuous glucose monitor in Germany for adults with type 2 diabetes, according to a May 19 report by MassDevice. The move adds a Germany-specific product aimed at a broader type 2 population as the San Diego-based company pushes further beyond the traditional intensive-insulin user base. The launch comes the same day MD+DI reported that a recent U.S. coverage decision could “basically double the addressable market” for continuous glucose monitoring, or CGM, in terms of covered people. Germany is the immediate market in this announcement, but the product sits inside a wider Dexcom effort to expand CGM use in type 2 diabetes. Dexcom has been publishing data and provider materials arguing that CGM can help adults with type 2 diabetes, including people not using insulin, improve glucose control and daily management. The company said in March that long-term Dexcom G7 use supported weight management and lower A1C in people with type 2 diabetes not on insulin therapy. (massdevice.com) ### What exactly did Dexcom launch in Germany? MassDevice reported on May 19 that Dexcom launched Dexcom Flex in Germany for adults with type 2 diabetes. The report described Flex as a new CGM offering for that market, giving Dexcom a product positioned specifically around type 2 use in Germany. Dexcom has not, in the materials surfaced here, framed Flex as replacing its broader G7 family. Dexcom’s public product pages continue to market G7 systems for type 2 diabetes, including a 15-day version in the United States, with messaging centered on real-time readings, alerts and easier day-to-day management. (investors.dexcom.com) ### Why does the U.S. coverage decision matter to this story? MD+DI reported on May 18 that Dexcom said a U.S. coverage decision would “basically double the addressable market” for CGM in the United States in terms of people who are covered. (massdevice.com) That comment appeared in MD+DI’s report on Dexcom’s coming G8 device and broader market expansion. The coverage point matters because reimbursement has been one of the main limits on wider CGM adoption in type 2 diabetes. (dexcom.com) Dexcom’s own U.S. materials say about 50% of commercially insured patients not on insulin are covered, compared with roughly 87% of commercially insured insulin users, while Medicare coverage applies to insulin users or people who experience hypoglycemia. ### How does this fit with Dexcom’s broader type 2 push? (mddionline.com) Dexcom said on March 11 that registry data presented at ATTD 2026 showed long-term Dexcom G7 use supported weight management and lowered A1C in people with type 2 diabetes who were not on insulin therapy. In that same announcement, the company said the findings reinforced the need to broaden CGM access beyond insulin-treated populations. (dexcom.com) Dexcom’s provider-facing materials also describe CGM as a tool to close what it calls knowledge gaps in type 2 diabetes care. The company’s patient materials say CGM can be useful for people with type 2 diabetes who are not at A1C goal, have low glucose events, or experience glucose swings. ### What comes next from Dexcom on this market? MD+DI reported that Dexcom expects to read out its T2NI randomized controlled trial data at the American Diabetes Association meeting in June. (investors.dexcom.com) That trial result is the next named milestone in Dexcom’s effort to support broader CGM use in people with type 2 diabetes who are not on insulin. June’s ADA meeting is also where investors, clinicians and competitors will be watching for more detail on Dexcom’s type 2 evidence base and product roadmap, including how Flex in Germany and future G8 plans fit into the company’s wider expansion strategy. (provider.dexcom.com) That last point is an inference based on Dexcom’s launch timing, its March type 2 data push and MD+DI’s report on coverage expansion. (mddionline.com)